StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for TOVX yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $0.32 | $0.29 | -9.06% | 2.6M |
| 05-18 | $0.28 | $0.30 | +5.39% | 1.5M |
| 05-19 | $0.28 | $0.27 | -5.92% | 2.0M |
| 05-20 | $0.26 | $0.30 | +13.34% | 3.1M |
| 05-21 | $0.31 | $0.30 | -3.80% | 0.9M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 |
|---|---|
Revenue | $300.00K |
Operating Income | $-2.13M |
Net Income | $-2.04M |
EPS (Diluted) | $-0.05 |
Total Assets | $38.25M |
Total Liabilities | $22.85M |
Cash & Equivalents | $14.43M |
Free Cash Flow OCF − CapEx | Not available |
Shares Outstanding | 45.89M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.